A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer

National Cancer Institute (NCI)1 site in 1 country580 target enrollmentJuly 1998

ConditionsHER2-negative Breast Cancer HER2-positive Breast Cancer Recurrent Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer

Interventionspaclitaxel quality-of-life assessment laboratory biomarker analysis trastuzumab

Drugspaclitaxel

Overview

Phase: Phase 3
Intervention: paclitaxel
Conditions: HER2-negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Enrollment: 580
Locations: 1
Primary Endpoint: Response rate (complete response [CR]) and partial response [PR])
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic. Drugs used in chemotherapy, such as paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known what regimen of paclitaxel is more effective with or without trastuzumab in treating patients with breast cancer.

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether "dose dense" (DD) treatment with paclitaxel via weekly 1-hour infusion has a significantly higher response rate than "standard" (S) paclitaxel treatment, regardless of human epidermal growth factor receptor 2 (HER-2/neu) status and assignment to Herceptin (trastuzumab). II. To determine if the addition of Herceptin to DD or S paclitaxel significantly improves the response rate as compared to DD or S paclitaxel alone for HER-2/neu non-overexpressing metastatic breast cancer (e.g., 0 or 1+). III. To determine whether the addition of Herceptin to chemotherapy treatment modifies the quality of life experienced by patients with HER-2/neu non-overexpressing metastatic breast cancer. IV. To determine whether the quality of life experienced by patients with metastatic breast cancer who have been treated with "standard" paclitaxel treatment differ from that of patients treated with "dose dense" paclitaxel treatment. V. To correlate amplification and overexpression of the growth factor receptor ErbB2 by immunohistochemistry and fluorescent in-situ hybridization (FISH) with response rate, time to progression, and overall survival of patients with metastatic breast cancer treated with paclitaxel chemotherapy and paclitaxel + Herceptin. VI. To correlate ErbB2 shed extracellular domain (ECD) with response rate, time to progression, and overall survival of patients with metastatic breast cancer treated with different doses and schedules of paclitaxel and paclitaxel + Herceptin. In addition, to follow patterns of ErbB2/ECD after treatment and upon relapse. SECONDARY OBJECTIVES: I. To evaluate time to progression and survival of patients with HER-2 overexpressing metastatic breast cancer treated with either DD or S paclitaxel plus weekly Herceptin. II. To evaluate time to progression and survival of patients with HER-2 non-overexpressing metastatic breast cancer treated with either DD or S paclitaxel alone or DD or S paclitaxel plus weekly Herceptin. III. To evaluate cardiac toxicity as measured by changes in LVEF from baseline to follow-up measurements. OUTLINE; Patients are assigned to 1 of 2 treatment groups. GROUP I (HER2/neu non-overexpressors): Patients are randomized to 1 of 4 treatment arms. ARM A: Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks. ARM B: Patients receive paclitaxel IV over 1 hour weekly. ARM C: Patients receive paclitaxel as in Arm A. Patients also receive trastuzumab IV weekly. ARM D: Patients receive paclitaxel as in Arm B and trastuzumab as in Arm C. GROUP II (HER2/neu overexpression): Patients are assigned to 1 of 2 treatment arms. ARM E: Patients receive paclitaxel and trastuzumab as in Arm C. ARM F: Patients receive paclitaxel and trastuzumab as in Arm D. In all arms, courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After the completion of study treatment, patients are followed up periodically for up to 5 years.

Registry

clinicaltrials.gov

Start Date

July 1998

End Date

July 2004

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

National Cancer Institute (NCI)

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically confirmed adenocarcinoma of the female breast which is inoperable, recurrent or metastatic
•HER-2/neu status must be known at the time of protocol registration; HER-2/neu assessment will be based on FISH analysis of either the primary tumor or a metastatic site; a scoring of 0 or 1+ by immunohistochemistry (IHC) is considered negative; 2+ is considered negative unless confirmed by FISH positivity, in which case it should be considered positive; 3+ by IHC is considered positive; for centers using FISH only, a positive FISH assay by itself is sufficient to determine HER-2 positivity
•Patients with the following prior therapy are eligible:
•Patients with 0-1 prior chemotherapy regimens for metastatic or locally advanced breast cancer, with the following exception: no prior taxane for metastatic/locally advanced breast cancer
•Patients with 0-1 prior chemotherapy regimens in the adjuvant setting; if adjuvant regimen included a taxane, patient must have been disease free for at least 12 months from completion of adjuvant therapy until relapse
•Patients must be \> 2 weeks from prior surgery, other than simple biopsy or placement of venous access device; patients must be \> 4 weeks from prior chemotherapy; patients must be \>6 weeks from nitrosoureas, melphalan, or mitomycin
•Patients must be \> 4 weeks from prior hormonal therapy unless tumor measurements document clear progression while on treatment; if progression is documented and toxicity from hormonal regimen has resolved, patients may be placed on study \> 1 week from prior hormonal therapy
•Prior Herceptin therapy is not allowed
•Patients with central nervous system metastases are eligible only if the patient has completed cranial irradiation at least 6 months prior, is currently asymptomatic, and is not currently receiving corticosteroids for this condition; patients with leptomeningeal carcinoma (carcinomatous meningitis) are not eligible
•MESURABLE DISEASE: Any mass reproducibly measurable in two perpendicular dimensions, examples include:

Exclusion Criteria

Not provided

Intervention: trastuzumab

Arm F (paclitaxel, trastuzumab)

Patients receive paclitaxel and trastuzumab as in Arm D.

Intervention: quality-of-life assessment

Arm F (paclitaxel, trastuzumab)

Patients receive paclitaxel and trastuzumab as in Arm D.

Intervention: laboratory biomarker analysis

Outcomes

Primary Outcomes

Response rate (complete response [CR]) and partial response [PR])

Time Frame: Up to 5 years

Multivariate logistic regression will be used to relate patient characteristics and pretreatment clinical variables with tumor response (complete or partial). Interim analyses will use a chi square statistic to compare response incidence by treatment arm with two-sided bounds constructed from the O'Brien-Fleming approach

Secondary Outcomes

Overall survival(Up to 5 years)
Time to disease progression:(Up to 5 years)
Duration of response(Length of time between response and disease progression, assessed up to 5 years)
Cardiac toxicity as measured by changes in LVEF(From baseline to up to 5 years)
Toxicity as assessed by CALGB Expanded Common Toxicity Criteria(Up to 5 years)
Change in quality of life (QOL)(From baseline to up to 9 months)
Correlation between ErbB2 and response to treatment(Up to 5 years)